Severe cholestasis due to adalimumab in a Crohn's disease patient

World Journal of Hepatology

Volumn 5, Issue 10, 2013, Pages 592-595

  Kim, Edward ^a   Bressler, Brian ^a   Schaeffer, David F ^a   Yoshida, Eric M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Adalimumab; Anti tumor necrosis factor agents; Cholestasis; Crohn's disease; Drug induced liver injury

Indexed keywords

EID: 84887340658     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v5.i10.592     Document Type: Article

References (11)

1. Sokolove J, Strand V, Greenberg JD, Curtis JR, Kavanaugh A, Kremer JM, Anofrei A, Reed G, Calabrese L, Hooper M, Baumgartner S, Furst DE. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. Ann Rheum Dis 2010; 69: 1612-1617 [PMID: 20448284 DOI: 10.1136/ard.2009.112136]
2. Grasland A, Sterpu R, Boussoukaya S, Mahe I. Autoimmune hepatitis induced by adalimumab with successful switch to abatacept. Eur J Clin Pharmacol 2012; 68: 895-898 [PMID: 22205272 DOI: 10.1007/s00228-011-1191-4]
3. Miehsler W, Novacek G, Wenzl H, Vogelsang H, Knoflach P, Kaser A, Dejaco C, Petritsch W, Kapitan M, Maier H, Graninger W, Tilg H, Reinisch W. A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. J Crohns Colitis 2010; 4: 221-256 [PMID: 21122513 DOI: 10.1016/j.crohns.2009.12.001]
4. Doyle A, Forbes G, Kontorinis N. Autoimmune hepatitis during infliximab therapy for Crohn's disease: a case report. J Crohns Colitis 2011; 5: 253-255 [PMID: 21575891 DOI: 10.1016/j.crohns.2010.12.007]
5. Tobon GJ, Cañas C, Jaller JJ, Restrepo JC, Anaya JM. Serious liver disease induced by infliximab. Clin Rheumatol 2007; 26: 578-581 [PMID: 16547695 DOI: 10.1007/s10067-005-0169-y]
6. Menghini VV, Arora AS. Infliximab-associated reversible cholestatic liver disease. Mayo Clin Proc 2001; 76: 84-86 [PMID: 11155419 DOI: 10.4065/76.1.84]
7. Goldfeld DA, Verna EC, Lefkowitch J, Swaminath A. Infliximab-induced autoimmune hepatitis with successful switch to adalimumab in a patient with Crohn's disease: the index case. Dig Dis Sci 2011; 56: 3386-3388 [PMID: 21597977 DOI: 10.1007/s10620-011-1748-1]
8. Adar T, Mizrahi M, Pappo O, Scheiman-Elazary A, Shibolet O. Adalimumab-induced autoimmune hepatitis. J Clin Gastroenterol 2010; 44: e20-e22 [PMID: 19593165 DOI: 10.1097/MCG.0b013e3181a745e7]
9. Hagel S, Bruns T, Theis B, Herrmann A, Stallmach A. Subacute liver failure induced by adalimumab. Int J Clin Pharmacol Ther 2011; 49: 38-40 [PMID: 21176723]
10. Mion F, Napoleon B, Berger F, Chevallier M, Bonvoisin S, Descos L. Azathioprine induced liver disease: nodular regenerative hyperplasia of the liver and perivenous fibrosis in a patient treated for multiple sclerosis. Gut 1991; 32: 715-717 [PMID: 2060883]
11. Romagnuolo J, Sadowski DC, Lalor E, Jewell L, Thomson AB. Cholestatic hepatocellular injury with azathioprine: a case report and review of the mechanisms of hepatotoxicity. Can J Gastroenterol 1998; 12: 479-483 [PMID: 9812167]